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A large  number  of quinones  have  been  associated  with  antitumor,  antibacterial,  antimalarial,  and  anti-
fungal activities.  Results  of  previous  studies  of  5-methoxy-3,4-dehydroxanthomegnin,  a naphthoquinone
isolated  from  Paepalanthus  latipes  Silveira,  Eriocaulaceae,  revealed  antitumor,  antibacterial,  immunomod-
ulatory,  and  antioxidant  activities.  In  this  study,  we  assessed  the  mutagenicity  and  metabolism-mediated
cytotoxicity  of  5-methoxy-3,4-dehydroxanthomegnin  by using  the  Ames  test  and  a microculture  neu-
tral red  assay  incorporating  an S9  fraction  (hepatic  microsomal  fraction  and  cofactors),  respectively.
We  also  evaluated  the  mutagenic  activity  in Salmonella  typhimurium  strains  TA100,  TA98, TA102,  and
TA97a,  as well  as the  cytotoxic  effect  on McCoy  cells  with and  without  metabolic  activation  in both
tests.  Results  indicated  that  naphthoquinone  does  not  cause  mutations  by substitution  or by addition
and  deletion  of  bases  in  the deoxyribonucleic  acid  sequence  with  and  without  metabolic  activation.  As
previously  demonstrated,  the in  vitro  cytotoxicity  of 5-methoxy-3,4-dehydroxanthomegnin  to McCoy
cells  showed  a signiﬁcant  cytotoxic  index  (CI50) of  11.9 g/ml.  This  index  was  not  altered  by  addition  of
the  S9  fraction,  indicating  that  the  S9 mixture  failed  to  metabolically  modify  the  compound.  Our  results,
allied  with  more  speciﬁc  biological  assays  in the  future,  would  contribute  to the  safe  use of  5-methoxy-
3,4-dehydroxanthomegnin,  compound  that  has  showed  in previous  studies  beneﬁcial  properties  as  a
potential  anticancer  drug.
© 2014  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
“For many centuries, plants have provided a rich source of
herapeutic agents and bases for synthetic drugs. Despite the
evelopment of organic synthesis, 25% of the drugs prescribed
orldwide are derived from plant sources, showing that plant
pecies are still an important source of new drugs” (Sacoman et al.,
008). Much research has been conducted on plants in popular
se, with the objective of identifying natural products with thera-
eutic potential (Balunas and Kinghorn, 2005; Gurib-Fakim, 2006;
ewman and Cragg, 2012).
∗ Corresponding author at: Department of Pharmaceutical Sciences, Federal Uni-
ersity of Espírito Santo – UFES, Avenida Marechal Campos 1468, 29043-900 Vitória,
S,  Brazil.
E-mail: rodrigo.kitagawa@ufes.br (R.R. Kitagawa).
http://dx.doi.org/10.1016/j.bjp.2014.12.001
102-695X/© 2014 Sociedade Brasileira de Farmacognosia. Published by Elsevier EditoraThe Eriocaulaceae family, commonly found in the States of Bahia
and Minas Gerais, Brazil, has been the source of several biolog-
ically active compounds. Paepalanthus, with about 500 species,
is one of its principal genus. A number of studies have demon-
strated that almost all species of Paepalanthus subgenus Platycaulon
possess naphthopyranone derivatives, including paepalantine and
8,8′-paepalantine dimer isolated from Paepalanthus bromelioides
(Vilegas et al., 1990; Coelho et al., 2000), planifolin isolated
from Paepalanthus planifolius (Santos et al., 2001; Varanda et al.,
2006), and 5-methoxy-3,4-dehydroxanthomegnin isolated from
Paepalanthus latipes Silveira, Eriocaulaceae, (Kitagawa et al., 2004,
2008).
The compound 5-methoxy-3,4-dehydroxanthomegnin (1) is
a naphthoquinone with potential therapeutic applications. Pre-
vious studies have shown that this compound has antitu-
mor  and immunomodulatory effects (Kitagawa et al., 2011),
as well as anti-Helicobacter pylori and antioxidant properties
 Ltda. All rights reserved.
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Kitagawa et al., 2012). The antitumor effect of 5-methoxy-3,4-
ehydroxanthomegnin may  be enhanced by association with
scorbic acid as demonstrated by a signiﬁcant cytotoxic index
CI) for McCoy cells. The enhanced effect is probably due to
ydrogen peroxide generated by ascorbate-driven 5-methoxy-3,4-
ehydroxanthomegnin redox cycling (Kitagawa et al., 2008).
Currently, interest is focused on cytotoxic compounds that
ppear to exert a beneﬁcial effect on key mechanisms involved
n the pathogenesis of cancer and infection diseases. Many active
ompounds that work by interfering with the function of DNA seem
o play a decisive role in antitumor activity (Harvey, 2008; Ma  and
ang, 2009; Sudan and Rupasinghe, 2014).
Short-term tests that detect genetic damage have allowed eval-
ation of the carcinogenic risks of chemicals to humans. The Ames
ssay, which is recommended for testing the mutagenicity of
hemical compounds with potential pharmacological applications
Varanda et al., 2006; Resende et al., 2012; Aardema, 2013), was
sed in the present study to evaluate in vitro the mutagenic effect
f 5-methoxy-3,4-dehydroxanthomegnin (1).
In vitro cytotoxicity tests simulate injury to cells from the
ested substances, which may  be caused by a number of incom-
lete mechanisms, during periods of exposure that are realistic for
cute toxicity (Benbow et al., 2010). The central point regarding
n vitro/in vivo comparisons refers to xenobiotic-metabolizing
apacity. Bioactivation is an important consideration in in vitro
ytotoxicity assays, since in vivo the test agent may  be bio-
ransformed. The incorporation of the S9 microsomal fraction
as been used in the study of metabolic activation of chem-
cals in a variety of cell culture models (Soares et al., 2006;
onsoni et al., 2013). The test is applicable to the analysis of
oxic ranges, for the detection of biotransformation of parent
ompounds, and for the evaluation of the cytotoxic effects of
hemotherapeutic agents (Borenfreund and Puerner, 1987). In this
tudy, we investigated in vitro metabolism-mediated cytotoxicity
f 5-methoxy-3,4-dehydroxanthomegnin using the S9 system. For
omparison, we evaluated cyclophosphamide, an indirect-acting
ytotoxicant employed in antineoplastic therapy, as the control of
iotransformation induction by the hepatic S9 fraction (Hill and
ill, 1984).
aterial and methods
lant material
Paepalanthus latipes Silveira, Eriocaulaceae, was  collected at
erra do Cipó in the Cadeia do Espinhac¸ o, Minas Gerais, Brazil,
nd authenticated by Professor Paulo Takeo Sano from the Insti-
ute of Biosciences, University of São Paulo. The voucher specimen
CFSC, 13846) is on ﬁle at the Herbarium in the Department
f Botany, Institute of Biosciences, University of São Paulo,
razil.
hemicals and culture mediaEagle medium was purchased from Adolfo Lutz (São Paulo,
razil), and fetal bovine serum from Cultilab (Campinas, Brazil).
imethyl sulfoxide (DMSO), nicotinamide adenine dinucleotide Farmacognosia 25 (2015) 16–21 17
phosphate sodium salt (NADP), d-glucose-6-phosphate disodium
salt, magnesium chloride (MgCl2), l-histidine monohydrate, d-
biotin, sodium azide, 2-anthramine, and 2-aminoﬂuorene were
purchased from Sigma Chemical Co. (St. Louis, MO,  USA). Oxoid
Nutrient Broth No. 2 (Oxoid; Basingstoke, UK) and Bacto Agar (BD
BactoTM; Sparks, MD,  USA) were used as bacterial media. d-glucose,
magnesium sulfate, citric acid monohydrate, anhydrous dibasic
potassium phosphate, sodium ammonium phosphate, monobasic
sodium phosphate, dibasic sodium phosphate, and sodium chlo-
ride were purchased from Merck (Whitehouse Station, NJ, USA).
Neutral red (NR) was obtained from Riedel-de-Haën AG (Seelze,
Hannover, Germany). The 5-methoxy-3,4-dehydroxanthomegnin,
isolated and characterized as previously described (Kitagawa
et al., 2004), was stored as stock solution at 10 mg/ml in
DMSO.
Metabolic activation system (S9 mixture)
The S9 fraction, prepared from livers of Sprague-Dawley
rats treated with the polychlorinated biphenyl mixture Aroclor
1254 (500 mg/kg), was purchased from Molecular Toxicology, Inc.
(Boone, NC, USA). The metabolic activation system consisted of S9
fraction (4%), 0.4 M MgCl2 (1%), 1.65 M KCl (1%), 1 M d-glucose-
6-phosphate disodium (0.5%), 0.1 M NADP (4%), 0.2 M phosphate
buffer (50%), and sterile distilled water (39.5%) (Maron and Ames,
1983).
Salmonella mutagenic assay
Mutagenic activity was tested by Salmonella/microsome assay,
using the Salmonella typhimurium tester strains TA97a, TA98,
TA100, and TA102 (kindly provided by B.N. Ames; Berkeley,
CA, USA), with and without metabolization by the preincuba-
tion method (Maron and Ames, 1983). The strains from frozen
cultures were grown overnight for 12–14 h in Oxoid Nutrient
Broth No. 2. The metabolic activation mixture (S9) was freshly
prepared before each test. Various concentrations of 5-methoxy-
3,4-dehydroxanthomegnin dissolved in DMSO were tested: 62.5,
125.0, 250.0, 500.0, and 750.0 g/plate for strains TA98, TA97a, and
TA100; 6.25, 12.5, 25.0, 50.0, and 75.0 g/plate for strain TA102.
These concentrations were selected based on a preliminary toxic-
ity test. In all subsequent assays, the upper limit of the dose range
tested was  either the highest nontoxic dose or the lowest toxic
dose determined in this preliminary assay. Toxicity was  apparent
as a reduction in the number of His+ revertants or as an alteration
in the auxotrophic background (i.e., background lawn). The vari-
ous concentrations of 5-methoxy-3,4-dehydroxanthomegnin were
added to 0.5 ml  of 0.2 M phosphate buffer (pH 7.4) or to 0.5 ml  of
4% S9 mixture combined with 0.1 ml  of bacterial culture and then
incubated at 37 ◦C for 20–30 min. After this time, 2 ml  of top agar
was added to the mixture and poured on to a plate containing
minimal agar. The plates were incubated at 37 ◦C for 48 h and the
revertant colonies were counted manually. All experiments were
analyzed in triplicate. The results were analyzed with the Salanal
statistical software package, adopting the Bernstein et al. (1982)
model. The data (revertants/plate) were assessed by analysis of
variance (ANOVA), followed by linear regression. The mutagenic
index (MI) was also calculated for each concentration tested, this
being the average number of revertants per plate with the test
compound divided by the average number of revertants per plate
with the negative (solvent) control. A sample was considered muta-
genic when a dose–response relationship was detected and a 2-fold
increase in the number of mutants (MI  ≥ 2) was observed with at
least 1 concentration (Santos et al., 2006). The standard mutagens
used as positive controls in experiments without the S9 mix-
ture were 4-nitro-O-phenylenediamine (10.0 g/plate) for TA98
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Table  1
Mutagenic activity and mutagenic index (MI) of 5-methoxy-3,4-dehydroxanthomegnin (naphthoquinone) at various concentrations in strains TA100, TA98, and TA97a of
Salmonella typhimurium in the presence (+S9) and absence (−S9) of metabolic activation.
Naphthoquinone
(g/plate)
Number of revertants/plate and (MI)
TA100 TA98 TA97a
−S9 +S9 −S9 +S9 −S9 +S9
0 147 ± 22 121 ± 13 22 ± 3 26 ± 1 218 ± 2 343 ± 6
62.5  151 ± 9 (1.08) 199 ± 33(1.32) 21 ± 4 (1.2) 28 ± 2 (1.27) 304 ± 28 (1.2) 332 ± 27 (1.05)
125  151 ± 8 (1.08) 176 ± 9 (1.17) 18 ± 3(1.05) 25 ± 2 (1.13) 277 ± 12 (1.1) 399 ± 10 (1.26)
250  154 ± 12 (1.10) 185 ± 30(1.23) 17 ± 2 (1.0) 26 ± 2 (1.18) 309 ± 22 (1.25) 476 ± 16 (1.51)
500  131 ± 14 (0.94) 185 ± 19 (1.23) 17 ± 3 (1.0) 27 ± 3 (1.22) 301 ± 10 (1.21) 398 ± 26 (1.26)
750  124 ± 10 (0.88) 216 ± 53 (1.44) 19 ± 2 (1.1) 27 ± 4 (1.22) 294 ± 16 (1.19) 431 ± 25 (1.36)
Control+ 957 ± 24 973 ± 10 1492 ± 28 2002 ± 60 1484 ± 32 1521 ± 31
0 = negative control: 75.0 l DMSO.
Positive controls: +S9 → 2-anthramine (2.5 g/plate) for TA100, TA98 and TA97a strains. −S9 → sodium azide (1.25 g/plate) for TA100; 4 nitro-o-phenylenediamine
(10.0  g/plate) for TA98 and TA97a. The results are reported as means ± SD.
* d with negative control.
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Table 2
Mutagenic activity and mutagenic index (MI) of 5-methoxy-3,4-
dehydroxanthomegnin (naphthoquinone) at various concentrations in strain
TA102 of Salmonella typhimurium in the presence (+S9) and absence (−S9) of
metabolic activation.
Naphthoquinone (g/plate) Number of revertants/plate and (MI)
TA102
−S9 +S9
0 400 ± 10 301 ± 5
6.25 355 ± 6 (0,93) 292 ± 17 (0.92)
12.5 401 ± 8 (1.05) 295 ± 38 (0.93)
25 384 ± 5 (1.01) 307 ± 8 (0.96)
50  389 ± 23 (1.02) 288 ± 15 (0.90)
75 379 ± 30 (1.0) 282 ± 22 (0.88)
Control + 1157 ± 54 1348 ± 66
0 = negative control: 75.0 l DMSO.
Positive controls: +S9 → 2-aminoﬂuorene (10.0 g/plate). −S9 → daunomycin
(3.0 g/plate). The results are reported as means ± SD.
* p < 0.05 (ANOVA) 5-methoxy-3,4-dehydroxanthomegnin concentrations com-
for in vitro metabolic activation assay.
Table 3
Cytotoxic midpoint (g/ml) on McCoy cells for 5-methoxy-3,4-
dehydroxanthomegnin and cyclophosphamide without and with the S9 metabolic
activation.
a ap < 0.05 (ANOVA) 5-methoxy-3,4-dehydroxanthomegnin concentrations compare
nd TA97a, sodium azide (1.25 g/plate) for TA100, and dauno-
ycin (3.0 g/plate) for TA102. In the experiments with metabolic
ctivation, 2-anthramine (2.5 g/plate) was used with TA98, TA97a,
nd TA100, and 2-aminoﬂuorene (10.0 g/plate) with TA102.
MSO served as the negative (solvent) control (75.0 l/plate).
ytotoxicity assay
McCoy cells (CCL1–ATCC/USA, from the cell culture section
f the Adolfo Lutz Institute, São Paulo, Brazil) were maintained
n Eagle medium with 7.5% fetal bovine serum. After trypsiniza-
ion, 0.2 ml  of medium containing approximately 104 cells/ml were
eeded into 96-well microtiter tissue culture plates and incu-
ated at 37 ◦C. After 24 h, the Eagle medium was removed and
he cells were placed in unmodiﬁed medium (control) or in
edium modiﬁed with various concentrations of 5-methoxy-3,4-
ehydroxanthomegnin (5, 10, 20, 40, 50, 80, and 100 g/ml) or
yclophosphamide (25, 50, 100, 150 g/ml) with and without the
9 mixture at 10%. After incubating for another 24 h, the medium
as removed and the plates were prepared for the NR assay
Borenfreund and Puerner, 1985). After brief agitation, the plates
ere transferred to a microplate reader (Spectra and Rainbow
Shell] Readers; Tecan, Austria) and the optical density of each
ell was measured using a 540 nm ﬁlter and a 620 nm reference
avelength. All experiments were performed at least four times,
sing three wells for each concentration of compound tested. The
ytotoxicity data were standardized by determining absorbance
nd calculating the corresponding chemical concentrations. Linear
egression analysis with a 95% conﬁdence limit was used to deﬁne
ose–response curves and to compute the concentrations of chem-
cal agents needed to reduce absorbance of the NR by 50% (IC50),
alled cytotoxic midpoint (Barile, 1994).
esults
Tables 1 and 2 show the mutagenicity results for 5-methoxy-3,4-
ehydroxanthomegnin which demonstrate that this compound
oes not possess mutagenic activity for the strains TA100, TA97a,
nd TA98, with MI  less than 2.0 at all tested concentrations
ith or without metabolic activation. The TA102 strain was
ound to be more sensitive to the toxic effects of 5-methoxy-
,4-dehydroxanthomegnin; thus, it was necessary to decrease the
oncentrations used with TA102 relative to the other strains. In
act, the lowest concentration used in the experiments with TA100,
A97a, and TA98 was close to the highest concentration used withpared with negative control.
TA102. Nevertheless, the TA102 strain did not display mutagenicity
in the absence or presence of metabolic activation.
The concentration–response curve for cytotoxicity was estab-
lished for 5-methoxy-3,4-dehydroxanthomegnin in the presence
and absence of an S9 mixture as an external metabolizing
system (Fig. 1). Table 3 shows the IC50 of 5-methoxy-3,4-
dehydroxanthomegnin and cyclophosphamide (control) for McCoy
cells in the presence and absence of the S9 system. The IC50 obtained
for 5-methoxy-3,4-dehydroxanthomegnin in the presence of the S9
mixture did not differ from that attained without the metabolizing
system. Exposure of the McCoy cells to cyclophosphamide with and
without S9 conﬁrms the efﬁcacy of the hepatic microsomal fractionCompound Without S9 With S9
5-Methoxy-3,4-dehydroxanthomegnin 11.9 ± 1.15 10.08 ± 0.38
Cyclophosphamide >150 21.6 ± 1.7
a Values are means ± SD (n = 3).
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iscussion
During the past few decades, plant research has revealed
everal chemical compounds with important pharmacological
ctivities. Some of these compounds have been incorporated
nto drugs such as antineoplastics-vinblastine and vincristine iso-
ated from Catharanthus roseus,  camptothecin derivatives obtained
rom Camptotheca acuminata,  derivatives of podophyllotoxin from
he rhizomes of Podophyllum peltatum and P. hexandrum, and
axol extracted from Taxus brevifolia (Cragg and Newman, 2005;
rivastava et al., 2005; Basmadjian et al., 2014). However, the
iterature also describes many plants containing mutagenic com-
ounds, such as furocoumarins, tannins, anthraquinones, alkaloids,
nd ﬂavonoids (Rietjens et al., 2005; Nesslany et al., 2009; Guterres
t al., 2013; Mininel et al., 2014). This evidence draws attention to
he importance of studying the genetic risks of plant compounds,
ince the presence of mutagens in medicines can be dangerous to
uman health.
Previous studies have shown that species belonging to Paepalan-
hus subgenus Platycaulon possess naphthopyranone derivatives.
he naphthopyranone paepalantine isolated from P. vellozioides
xhibited strong mutagenicity and cytotoxicity (Varanda et al.,
997). The genotoxic potential of paepalantine was also demon-
trated by Tavares et al. (1999) in in vivo assays with bone marrow
ells of Wistar rats. The mutagenic activity of planifolin isolated
rom P. planifolius was tested through Salmonella/microsome
ssays, with results indicating that this naphthopyranone dimer
aused mutations by substitution and by addition and deletion
f bases in the DNA sequence. Moreover, its mutagenic potential
ncreased in the presence of metabolization. These results, allied to
he chemical structure, suggest that planifolin may  act as an inter-
alating agent in the DNA molecule (Varanda et al., 2006). In the
resent study, we assessed the mutagenic activity of 5-methoxy-
,4-dehydroxanthomegnin (1) using Salmonella/microsome assays.
he compound 5-methoxy-3,4-dehydroxanthomegnin was not
utagenic to strain TA98, which is used to detect frameshift muta-
ions. Substitution of DNA bases in strain TA100 and oxidative DNA
amage in strain TA102 were not detected. No mutagenicity was
bserved in the TA97a strain, which detects frameshift mutations
hat are sensitive to heavy metal mutagens. The results were
lso negative for all the S. typhimurium strains tested with the S9
ixture.d cyclophosphamide (B) on McCoy cells with (red line) and without the S9 (black
t three independent experiments carried out in triplicate. (For interpretation of the
However, data reported in the literature reveal that some
quinones, including naphthoquinones, present mutagenicity after
metabolization. Chesis et al. (1984) concluded that the muta-
genicity of quinones was mainly due to one-electron reduction
of quinones to semiquinones via the formation of superox-
ide anion radical (O2•−) and, subsequently, hydrogen peroxide
(H2O2). Tikkanen et al. (1983) observed that naphthoquinones
with 1 or 2 hydroxyl and/or methyl substituents are mutagenic
with metabolic activation. Nevertheless, it seems that the posi-
tion of substituents, as well as the number of substituents, is
important for mutagenicity. This point seems to explain the
absence of mutagenicity of 5-methoxy-3,4-dehydroxanthomegnin,
which has hydroxyl and methyl substituents and did not
present mutagenicity in tests with or without metaboliza-
tion.
Considerable interest has been focused on short-term in vitro
cytotoxicity assays with cultured cells for evaluation of acute tox-
icities of chemical agents and pilot studies in drug development.
Such assays would not only curtail the use of animals for median
lethal dose (LD50) and similar tests, but would serve as an econom-
ical approach to the rapid screening of xenobiotics (Greene et al.,
2010).
Cytotoxicity due to direct-acting chemicals is readily demon-
strable in vitro. However, the toxicity of many chemicals is
dependent upon metabolic activation, usually catalyzed by the
microsomal cytochrome P-450-dependent monooxygenase sys-
tem, and the majority of cell lines currently used in in vitro
cytotoxicity tests possess little intrinsic drug-metabolic activity.
Consequently, problems arise when metabolism-mediated cyto-
toxic events are studied in vitro. One possible answer to this
problem is the coincubation of cultured cells with metabolically
active rodent liver fractions, in a manner similar to their use in
in vitro mutagenesis assays (Gonzalez, 2005; Li et al., 2012; Cole
et al., 2014).
In previous studies, 5-methoxy-3,4-dehydroxanthomegnin
showed signiﬁcant in vitro cytotoxicity to McCoy cells in the NR
microculture test compared with cis-diamminedichloroplatinum
(cisplatin), one of the most widely used chemotherapeutic drugs
(Kitagawa et al., 2004). Our results indicated that combined treat-
ment with 5-methoxy-3,4-dehydroxanthomegnin and hepatic S9
microsomal fraction did not alter the cytotoxicity of this naphtho-
quinone.
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One hypothesis explaining the same cytotoxic potential of
-methoxy-3,4-dehydroxanthomegnin with and without the S9
icrosomal system is that this compound does not act as a sub-
trate for the enzymatic system. Previous studies explored redox
ycling of 5-methoxy-3,4-dehydroxanthomegnin in a nonenzy-
atic system. In this study, we used the NR assay to evaluate
he ability of ascorbic acid associated with 5-methoxy-3,4-
ehydroxanthomegnin to cause cell death in the same cell
ine. The synergic effect of ascorbic acid on 5-methoxy-3,4-
ehydroxanthomegnin (1) resulted in a CI that was seven times
ower than the index for 5-methoxy-3,4-dehydroxanthomegnin
lone added to the McCoy cell line. The observed synergic effect
as most probably due to H2O2 generated by ascorbate-driven
-methoxy-3,4-dehydroxanthomegnin redox cycling (Kitagawa
t al., 2008), indicating that the association of 5-methoxy-3,4-
ehydroxanthomegnin with ascorbic acid may  be promising in the
reatment of solid tumors that are deﬁcient in antioxidant defenses.
The results of this study investigating the mutagenic activ-
ty and metabolism-mediated cytotoxicity of 5-methoxy-3,4-
ehydroxanthomegnin, allied in the future with more speciﬁc
iological assays, will contribute to the safe use of 5-methoxy-
,4-dehydroxanthomegnin, signifying its beneﬁcial properties as
 potential anticancer drug.
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